$RVNC - down 20 percent last two days Can the market be more negative on this one? Supposed to be best in class drug. EOLS which is selling an inferior product is having EV of 810mm with 2024 revenue guidance of 255mm. 3.2x multiple RVNC minimum revenue guidance is 280mm. EV is 670mm. 2.4x. I.e. the market is saying EOLS has better prospect than RVNC now. Make no sense to me. Is it really that hard to roll out a product properly? They seems to execute well with RHA. How can they perform so messy with Daxxify? Should Foley be fired?